A double-blind, double-dummy clinical trial was conducted in which the efficacy of
cyclandelate 1600 mg daily was compared with that of
flunarizine 10mg daily in 40 patients (25 men and 15 women) with
dementia of cerebrovascular origin. Parameters were assessed before treatment, and after 45 and 90 days of
therapy. At 90 days, significant improvements were observed in patients given
cyclandelate in measurements of P100 latency in the left eye, neurological impairment,
dementia scores, ischaemia scores, Gottfries
mental deterioration scale, Hamilton depression scores, short term visual memory, long term memory, Bender-Gestalt test and Koh's blocks test. In
flunarizine recipients, improvements were observed in neurological impairment, ischaemia scores, Gottfries scale and Hamilton depression scores. Patients treated with
cyclandelate showed significantly greater ameliorations in symptoms as assessed by the ischaemia scale, evoked visual potential, visual memory and Koh's block test compared with those given
flunarizine. However, in none of the parameters was
flunarizine superior to
cyclandelate.